Introduction
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by BM infiltration with immature lymphoblasts derived from transformed T cell precursors (1). A common cause of T-ALL is the dysregulation of signaling pathways that control T cell development in the thymus (2), such as NOTCH1, which is a key oncogenic player in human T-ALL (3). NOTCH1 is a member of the NOTCH family (NOTCH1-NOTCH4) of conserved transmembrane receptors that regulate survival, proliferation, and cell-fate decisions in different cell types, including T lymphocytes (4, 5) . Binding of mammalian Notch receptors to Delta or Jagged ligands triggers a series of enzymatic cleavages by ADAM metalloproteases and γ-secretase that release the intracellular Notch domain (ICN). ICN translocates to the nucleus and forms a transcriptional complex with the DNA-binding protein CSL/RBPJ and coactivators of the mastermind-like (MAML) family (6) . NOTCH1 plays a crucial role in T-ALL pathogenesis, as illustrated by the fact that over 60% of human T-ALLs contain gain-of-function NOTCH1 mutations that lead to ligand-independent NOTCH1 signaling (7) .
Seminal studies have addressed the impact of dysregulated Notch signaling in T cell leukemogenesis using a well-defined murine model, wherein expression of constitutively active intracellular Notch1 (ICN1) in hematopoietic stem/progenitor cells (HSPCs) leads to extrathymic T cell development in the BM and results in a fatal murine T-ALL that resembles the human disease (8, 9) . Weaker NOTCH1 alleles, such as those commonly found in human T-ALL, fail to initiate overt T cell leukemia in mice, but generate signals of sufficient strength to induce ectopic development and BM accumulation of aberrant CD4 + CD8 + double-positive (DP) preleukemic T cells, which eventually cause an aggressive T-ALL in concert with other genetic alterations (10) . Consequently, Notch-associated leukemogenesis is characterized by the initial interaction of preleukemic cells with the BM microenvironment, which may be a crucial step providing the supportive signals required for leukemia initiation (11) . Therefore, either when the NOTCH1 mutation acts as the initial driving genetic event of T-ALL (12) or when oncogenic NOTCH1 complements other leukemogenic signals (10, 13), BM NOTCH1 is a prevalent signaling pathway in T cell acute lymphoblastic leukemia (T-ALL), but crucial NOTCH1 downstream signals and target genes contributing to T-ALL pathogenesis cannot be retrospectively analyzed in patients and thus remain ill defined. This information is clinically relevant, as initiating lesions that lead to cell transformation and leukemia-initiating cell (LIC) activity are promising therapeutic targets against the major hurdle of T-ALL relapse. Here, we describe the generation in vivo of a human T cell leukemia that recapitulates T-ALL in patients, which arises de novo in immunodeficient mice reconstituted with human hematopoietic progenitors ectopically expressing active NOTCH1. This T-ALL model allowed us to identify CD44 as a direct NOTCH1 transcriptional target and to recognize CD44 overexpression as an early hallmark of preleukemic cells that engraft the BM and finally develop a clonal transplantable T-ALL that infiltrates lymphoid organs and brain. Notably, CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression, highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis. The observed therapeutic benefit of anti-CD44 antibody administration in xenotransplanted mice holds great promise for therapeutic purposes against T-ALL relapse.
The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model The observed engraftment of ICN1-transduced CB progenitors in RAG-2 -/-× γc -/-mice contrasted with results from a previous study wherein no peripheral repopulation of NOD/SCID mice with ICN1 + human cells was observed (15) . Thus, ICN1 + cells in our model could represent preleukemic cells able to eventually generate a human leukemia. However, such ICN1 + cells transiently engrafted the PB and showed repopulation kinetics indistinguishable from those of control GFP + cells. Both reached maximal numbers at 7 weeks after transplant, but decreased significantly by 10 weeks ( Figure 1F ) and disappeared by 15 to 17 weeks (data not shown). Therefore, enforced NOTCH1 signaling in human HSPCs is able to promote early events associated with preleukemia generation and leukemia onset in mice, including ectopic generation of aberrant DP T cells (8) ; such putative preleukemic cells engrafted transiently in RAG-2 -/-× γc -/-mice, with no evidence of leukemia generation, at least during the follow-up period of 17 weeks.
BM infiltration with transformed immature lymphoblasts derived from intrathymic T cell precursors is a common feature of T-ALL (1, 17). Therefore, thymus exit and exposure to a BM-supportive niche may be part of the T-ALL oncogenic program undertaken by preleukemic cells, as proposed for other hematologic neoplasias (11) . To investigate whether NOTCH1 signaling contributes to that program, we analyzed BM seeding and engraftment potential of CD34 + CD44 + CD1a -early T cell precursors (ETPs) isolated from the human postnatal thymus ( Figure 2A ) and transplanted into RAG-2 -/-× γc -/-mice upon transduction with either the ICN1 or the only-GFP vectors. We found that GFP-transduced ETPs reached the host thymus at 1 week after transplant, expanded in situ over 6 to 8 weeks, and disappeared after 10 weeks ( Figure  2B ), as observed with nontransduced thymocytes (not shown); however, they were unable to engraft the BM ( Figure 2C ). In contrast, ETPs expressing ICN1 recapitulated the behavior of ICN1 + HSPCs, as they efficiently engrafted the host BM for up to 10 to 12 weeks ( Figure 2C ) and also transiently repopulated the host thymus ( Figure 2B ). Importantly, as observed with HSPCs, ICN1 + ETPs generated ectopic DP cells in the BM, which were indistinguishable from their ICN1 + thymus counterparts in terms of CD4, CD8, and CD3-TCR-αβ expression ( Figure 2D ), but they aberrantly displayed upregulated levels of CD44 ( Figure 2E ). To assess whether ICN1 was able to improve cell engraftment by modulating homing into the BM, ICN1 + and GFP + ETPs were next assayed in short-term homing assays, which showed that they displayed similar homing kinetics, as both reached the BM as early as at 4 hours after transplant and remained at equivalent numbers for up to 1 week ( Figure 2F ). However, GFP + and nontransduced control ETPs dropped thereafter and became essentially undetectable by 2.5 weeks, while ICN1 + cell numbers increased steadily (up to 1000-fold) during the first 3 to 4 weeks after transplant ( Figure  2 , C and F). Therefore, active NOTCH1 does not markedly affect BM seeding of ETPs, but promotes their ectopic differentiation and expansion, likely contributing to the leukemogenic program.
Aberrant CD44 expression is an early hallmark of mutant NOTCH1 signaling and extrathymic T cell development. Upregulation of CD44 has been observed in preleukemic DP cells derived ectopically from murine BM progenitors expressing ICN1 (13, 17, 18) , but a relationship between Notch activation and CD44 expression, although suggested, has not been studied in detail.
Recognizing the preleukemogenic events associated with aberrant NOTCH1 signaling must be clinically relevant, as it may lead to the identification of specific targets for developing improved therapeutic strategies to fight disease relapse, which is a main T-ALL clinical issue. However, retrospective analysis of human leukemic onset is unfeasible, and understanding the stepwise impact of NOTCH1 mutations on human T-ALL pathogenesis demands the availability of suitable in vivo models whose generation has been previously addressed, but has been more difficult than anticipated (15) . Here, we have approached this aim using immunodeficient mice reconstituted with primary human cord blood (CB) HSPCs expressing constitutively active NOTCH1 and show the successful generation de novo of a clonal human leukemia that resembles T-ALL in patients. This T-ALL model has allowed the delineation of pathogenic events associated with the onset of the human disease. In particular, the identification of the adhesion molecule CD44 as a direct NOTCH1 target required for BM engraftment and LIC activity of human T-ALL xenografts highlights the importance of targeting the NOTCH1/ CD44 axis in future therapeutic interventions.
Results

Oncogenic NOTCH1 drives BM engraftment and ectopic T cell development of human HSPCs and intrathymic precursors.
In an attempt to generate a human T-ALL in vivo, we took advantage of the oncogenic Notch1 approach, previously reported to induce an aggressive murine T-ALL (8, 9) . To this end, CD34 + CD133
+ HSPCs isolated from human umbilical CB ( Figure 1A ) were transduced with a bicistronic retroviral vector encoding either constitutively active ICN1 and GFP as reporter or GFP alone, and cells were then transplanted into immunodeficient RAG-2 -/-× γc -/-mice. Flow cytometry analysis of sequential BM aspirates revealed that enforced ICN1 expression significantly boosted human HSPC engraftment in mouse BM (25-fold at 9 weeks after transplant), but not in spleen and thymus ( Figure 1B ). Most BM grafting ICN1 + human cells displayed an aberrant CD4 + CD8
+ DP phenotype characteristic of immature thymocytes (>90% at 9 weeks after transplant; Figure 1 , C and D) and showed unexpected high levels of the adhesion molecule CD44, specifically of the standard CD44 isoform (not shown), which is downregulated in conventional DP thymocytes ( Figure  1E ). A major proportion of ICN1 + DP ectopic T cells expressed the CD3-TCR-αβ complex, as did ICN1 + DP cells developing in the thymus, but about 25% displayed low CD3 expression and lacked both TCR-αβ ( Figure 1D ) and TCR-γδ (not shown), suggesting a differentiation blockade at the pre-TCR + stage (16) . In all animals, human ectopic T-lineage cells were exclusively derived from ICN1-transduced progenitors, whereas control GFP-transduced HSPCs differentiated mostly into CD19 + B lymphocytes in the BM and also produced a minor CD13 + myeloid subset, similarly to nontransduced HSPC controls (Figure 1, C and D) . Importantly, ICN1 + T cells also reached the peripheral blood (PB) and spleen of transplanted mice, but essentially all of them displayed a CD4 + or CD8 + single-positive (SP) phenotype of conventional T cells, and very few showed the aberrant DP phenotype of their BM counterparts ( Figure 1C ). ICN1 + progenitors also produced B cells that colonized the PB and spleen, although at very reduced proportions compared with GFP + controls ( Figure 1C ). . (D) CD44 expression levels of human CD4 ISP, DP pre-TCR, and DP TCR-αβ cells generated at 2, 3, and 6 weeks after transplant, respectively, in the BM and thymus of mice shown in A or at 9 weeks after transplant in the BM and thymus of mice shown in B. CD44 expression of control cells generated from either ETPs or CB HSPCs transduced with GFP (GFP + ) in the thymus and of human B cells generated in the BM from GFP + HSPCs is also shown. MFI ± SEM combined results from 6 (ETPs) and 3 (HSPCs) independent experiments, with a total of 3 to 9 mice per group are shown. Data were corrected by the FDR method. (E and F) Relative mRNA expression of CD44, HES1, IL7R, and IL2RG genes analyzed by qPCR and normalized to GAPDH in GFP-or ICN1-transduced human ETPs after 36 hours of transduction (C) or in DP thymocytes and BM ectopic DP cells derived from GFP-or ICN1-transduced human ETPs at 4 weeks after transplant. Data are shown as mean ± SEM of triplicates (n = 5). **P < 0.01; ***P < 0.001; ****P < 0.0001. jci.org
Volume 128 Figure 3C ), while their GFP + control intrathymic counterparts showed downregulated levels of CD44 ( Figure  3D ). Quantitative gene expression analyses of ICN1-transduced ETPs revealed that CD44 upregulation was induced at the transcriptional level as early as at 36 hours after transduction, when Notch target genes HES1 and IL7R were concurrently upregulated, but the unrelated IL2RG gene remained unchanged ( Figure  3E ). Transcriptional upregulation of Notch targets was observed as well in ectopic ICN1 + DP CD44 hi cells arising in the BM at 4 weeks after transplant, as compared with control DP thymocytes ( Figure  3F ). Collectively, these results provide evidence of a functional association between NOTCH1 activation and CD44 gene expression and indicate that CD44 upregulation is one of the earliest hallmarks of sustained NOTCH1 signaling, which is selectively associated with aberrant extrathymic T cell development.
CD44 is a direct transcriptional target of Notch1 in T-ALL cells.
Supporting a direct role of NOTCH1 signaling in the induction of aberrant CD44 expression, enforced ICN1 expression induced CD44 upregulation at the clonal level in SupT1 and CUTLL1 T-ALL cell lines that display constitutive NOTCH1 activation and CD44 expression (19) (Supplemental Figure 2, A and B) . Conversely, constitutive CD44 expression was downregulated upon transduction with a dominant negative form of the Notch coactivator MAML1 (dnMAML1) (Supplemental Figure 2A) . These results were confirmed in mRNA expression assays showing that NOTCH1 signaling regulates CD44 as well as HES1 and IL7R transcriptional levels in a MAML1-dependent manner (Supplemental Figure 2C) . Further experiments provided formal proof that CD44 is a direct NOTCH1 target. In particular, searching for putative CSL/RBPJ-binding sites in a human CD44 genomic sequence (Ensembl Gene database; https://uswest.ensembl.org:8443/sitedown.html) covering 5 kb upstream of the transcriptional start site (TSS) revealed 4 predicted CSL-binding sites at positions -4.7, -4.4, -3.8, and -3.5 kb (sites 1, 2, 3, and 5, respectively), which are conserved in nonhuman primates, and one at position -3.6 kb (site 4), also conserved in rodents. Reporter assays performed in SupT1 T-ALL cells transfected with a luciferase vector, which included the CD44 genomic region spanning the 5 putative CSL-binding sites (-4.8 to -3.5 kb), confirmed that ectopic ICN1 induced a significant transcriptional activity that was abolished by dnMAML1 ( Figure 4A) . Moreover, ChIP assays demonstrated that endogenous ICN1 expressed in CUTLL1, SupT1, and HPB-ALL T-ALL cell lines was associated in vivo with the CSL/RBPJ-binding motifs 1, 2, 3, and 5 in the CD44 gene and, as expected, also with the wellknown NOTCH1 target MYC (20) (21) (22) (Figure 4 , B and C). Sitedirected mutagenesis confirmed the RBPJ-dependent autonomous functionality of those sites ( Figure 4D ). Therefore, CD44 is a CSL/MAML1-dependent direct NOTCH1 target in human T-ALL.
A recent study by Aster's group showed that direct NOTCH1 target genes in T-ALL could be transcriptionally regulated by dynamic NOTCH1 binding to H3K27ac-marked superenhancers that frequently overlap with RUNX1-binding sites (23) . Importantly, based on their ChIP-sequencing (ChIP-seq) raw data (NCBI's Gene Expression Omnibus database; GEO GSE51800), we identified 2 dynamic NOTCH1 sites located 55-60 kb upstream of the CD44 gene, near RUNX1 sites, which are strongly associated with H3K27ac marks sensitive to Notch signaling alterations ( Figure  4E ). Therefore, NOTCH1 may also activate CD44 gene expression through dynamic interactions with superenhancers, as shown for other NOTCH1 targets, such as IL7R (23) .
Ectopic CD44 hi DP T cells include preleukemic cells that generate an aggressive human T-ALL. The finding that NOTCH1 signaling directly regulates CD44 transcription suggests that CD44 might be upregulated in preleukemic cells as part of the T-ALL oncogenic program. This possibility could not be confirmed in RAG-2 -/-× γc -/-mice, wherein ICN1 + DP CD44 hi aberrant cells engrafted transiently with no signs of leukemia progression ( Figure  1F and Figure 2C ). Importantly, these results concurred with the unexpected finding that control HSPCs also engrafted transiently in our model ( Figure 1F ), suggesting that the RAG-2 -/-× γc -/-mouse strain is not optimal for assaying human hematopoietic engraftment and repopulation. To overcome this possible limitation, we moved to the NSG strain, which has been reported to support greater human engraftment in BM than other strains of mice (24), and assessed whether enforced ICN1 expression is leukemogenic for human HSPCs in NSG mice. Thus, ICN1-transduced (7.4% ± 1.7% ICN1 + ) human HSPCs were transplanted into 6-to 10-weekold NSG mice, and sequential BM aspirates were then analyzed by flow cytometry for the presence of ICN1 + and ICN1 -human cells. We found that all NSG transplanted mice, in contrast with RAG-2 -/-× γc -/-mice, supported multilineage (T, B, and myeloid cells) engraftment from control ICN1 -human HSPCs during a follow-up period of 10 months ( Figure 5A and data not shown) and that 50% simultaneously displayed long-term engraftment of ICN1 + cells ( Figure 5B and Table 1 ). Strikingly, all animals with ICN1 + cell engraftment developed symptoms of disease and died of an aggressive T cell leukemia, with a median survival of 240 days ( Figure 5C ). Diseased mice showed up to 100-fold higher numbers of ICN1 + cells than ICN1 -nontransduced cells in the BM (up to 10 9 in absolute numbers; Figure 5D ), together with a high infiltration of peripheral organs, such as spleen (up to 3.4 × 10 8 ) and liver (up to 10 8 ), but thymus infiltration was lower, and PB infiltration was observed in 20% of mice (Table 1 and Figure  5D ). This represents the first model, to our knowledge, of de novo generation of a human T-ALL in vivo.
Immunophenotypic analyses of sequential BM aspirates performed over a 9-month follow-up period revealed that engrafted ICN1 + cells in NSG mice were mostly DP T cells that expressed either the TCR-αβ or the pre-TCR, together with aberrantly high levels of CD44, and this phenotype was also observed in ICN1 + cells infiltrating the spleen and liver (Figure 5 , E-G). Supporting their leukemogenic nature, BM ICN1 + DP cells displayed a restricted TCR-Vβ repertoire ( Figure 5H ) and, like spleen and liver ICN1 + cells (not shown), they were able to serially transfer an aggressive T-ALL disease to secondary and tertiary recipients (Table 1) . Together, these data provide formal proof that the bulk of human ICN1 ents was increased by 28-fold, as revealed by tertiary transplants (Table 1 ) . Increased LIC activity in sequential transplants resulted in a more aggressive disease with shorter latency, which correlated with an enhanced infiltration of leukemic DP CD44 hi cells in blood, spleen, liver, and brain. Collectively, these data demonstrate that constitutive NOTCH1 signaling can induce a human aggressive leukemia in NSG mice that resembles T-ALL arising in patients.
CD44 is required for BM engraftment of NOTCH1-induced preleukemic cells and primary T-ALL cells.
The role of CD44 as a critical mediator of interactions between normal HSPCs and the BM microenvironment has been known for many years (25, 26) , and the expression of CD44 in some cancer-initiating cells has also been described more recently (27) . Considering the critical role of the BM microenvironment in normal and neoplastic hematopoiesis (11), we sought to investigate the contribution of CD44 to NOTCH1-induced BM engraftment and leukemia progression. Thus, we first assessed the role of CD44 in BM engraftment of aberrant human cells derived from ICN1-transduced ETPs infused into Rag2 -/-× γc -/-mice and found that cell treatment before transplantation with a neutralizing mAb that blocks CD44 interaction with its ligands (515, IgG1, BD Bioscience) prevented the engraftment and ectopic development of aberrant ICN1 + DP T cells in the BM, as compared with cells pretreated with an isotypic IgG1 control ( Figure 6A ). The participation of CD44 in BM engraftment was confirmed in a therapeutic assay wherein Rag2 -/-× γc -/-mice transplanted with untreated ICN1-transduced ETPs were subjected to serial i.p. administration of the blocking anti-CD44 mAb HP2/9 (IgG1) (28, 29) , starting at day 5 after transplant ( Figure 6B ), when ETPs have already seeded the host BM ( Figure 2F and data not shown). We found a significant reduction (>100-fold) of ICN1 + T cell ectopic generation and expansion in anti-CD44-treated 
CD44 targeting prevents LIC function and progression in vivo of human T-ALL.
To directly explore the therapeutic potential of CD44 targeting, we next examined human T-ALL progression in mice subjected to anti-CD44 treatment once the disease was established. Two primary human T-ALLs with active NOTCH1 and distinct expression levels of CD44 (T-ALL1 or T-ALL2) (Supplemental Figure 4) were independently transplanted into Rag2 -/-× γc -/-mice, which were then subjected to serial i.p. injections of either HP2/9 anti-CD44 mAb or control IgG1 during 4 weeks, starting at different times after transplant, when increasing proportions of T-ALL cells representative of disease severity had engrafted the BM ( Figure 7A) . In a first group of mice, treatment started at 1 week after transplant, when incipient BM engraftment of T-ALL cells was observed (3.8% ± 1.6%) and no PB infiltration was evident (not shown). Analysis of sequential BM aspirates of IgG1-treated mice revealed that T-ALL engraftment increased progressively to 95% or more at 5 weeks after transplant, when a significant It is currently believed that the microenvironmental context can enable and modify hematopoietic neoplasia (11) . Therefore, we ought to investigate whether CD44 could also control the engraftment of T-ALL cells within the BM niche. To this end, primary leukemic cells that expressed active NOTCH1 and high CD44 levels (Supplemental Figure 4) , obtained from a T-ALL patient (T-ALL1), were loaded with anti-CD44 mAb or control IgG1 prior to transplantation into Rag2 -/-× γc -/-mice. Kinetic analyses showed that anti-CD44 pretreatment significantly impaired T-ALL engraftment and fully prevented leukemia burden and infiltration of thymus, spleen, and PB during a follow-up period of 11 weeks, as compared with IgG1-treated T-ALL cells ( Figure 6E ). These data indicate that CD44-mediated interactions of T-ALL cells with the BM microenvironment might control leukemic engraftment and further progression of the disease. Therefore, CD44 targeting may be a promising therapeutic strategy against T-ALL. -/-× γc -/-mice. Relative T-ALL1 cell numbers infiltrating the BM, PB, spleen, and thymus of 4 mice/group were analyzed at the indicated times after transplant (n = 3). *P < 0.05; **P < 0.01; ****P < 0.0001. 7F). Therefore, in vivo administration of anti-CD44 impairs LIC function. Likewise, LIC function was diminished in T-ALL cells recovered from mice subjected to late anti-CD44 treatment, starting at 8 weeks after transplant, when a severe disease with massive BM engraftment (94% ± 4%) and evident PB infiltration (9% ± 2%) was developed. Accordingly, secondary hosts transplanted with such cells showed prolonged survival (from 61 to 100 days) compared with control mice (data not shown). Collectively, these data indicate that CD44 is essential to the LIC activity and progression in vivo of human T-ALL leukemic cells.
The clinical implications of these findings prompted us to investigate the potential mechanism underlying impaired T-ALL engraftment and progression following anti-CD44 treatment. We found that the HP2/9 anti-CD44 mAb mediated very poor complement-dependent cytotoxicity (CDC) against T-ALL cells in an in vitro assay (Supplemental Figure 5A) , suggesting that CDC-induced killing of targeted T-ALL cells is not induced by HP2/9 in vivo. Accordingly, we found that few but detectable numbers of HP2/9 mAb-loaded T-ALL cells transplanted into Rag2
-/-× γc -/-mice, identified by their CD7 + CD5 + phenotype, were able to seed the mouse BM at very early times after transplant (5 hours, 24 hours, and 7 days) (Supplemental Figure 5B) . More importantly, such T-ALL cells showed reactivity with a PE-coupled anti-mouse IgG1 Ab, indicating that the HP2/9 mAb persisted in vivo on the surface of essentially all transplanted cells (Supplemental Figure  5C ), although HP2/9 binding seemed to decrease gradually over time (Supplemental Figure 5D) . As a whole, these data suggest that anti-CD44 treatment impairs T-ALL engraftment in part by blocking the interaction of CD44 with its ligands expressed in the BM microenvironment, although a cytotoxic effect of the mAb in vivo cannot be formally excluded.
To confirm that in vivo treatment with the anti-CD44 HP2.9 mAb results in reduced T-ALL engraftment and progression by a CDC-independent mechanism, we extended our study to NSG mice, wherein complement function is impaired due to a 2 bp deletion in the coding region of the hemolytic complement gene (34) . Notably, we found that HP2/9 mAb administration to NSG mice transplanted with T-ALL cells over 7 weeks, starting at 1 week after transplant ( Figure 8A ), reproduced the impaired progression of T-ALL observed in Rag2 -/-× γc -/-mice and resulted in a striking reduction of BM engraftment and leukemia burden, with no signs of splenomegaly, as compared with that in IgG1-treated mice (Figure 8, B and C) . These results confirm that anti-CD44 administration impairs leukemia progression in vivo by a CDC-independent mechanism. In addition, FACS analyses revealed that the very few T-ALL cells recovered from the BM of treated NSG mice displayed high reactivity with PE-coupled anti-IgG1, confirming the persistence of high levels of the HP2/9 mAb on the surface of T-ALL cells during the whole treatment period (Figure 8, D and E) . We found no evidence of a cytotoxic effect of the HP2/9 mAb bound on the cell surface, as the HP2/9 mAb was unable to induce cell apoptosis or cell-cycle arrest of T-ALL cells, at least in vitro (Supplemental Figure 5 , E and F). Therefore, we concluded that anti-CD44 mAb may impair T-ALL progression by blocking the ability of leukemic cells to interact with their supportive stromal niches. The interaction of CD44 with its major BM ligand hyaluronate (HA) (28) may provide the critical supportive signals that are impeded in the leukemia burden was evident in PB and spleen (up to 60% and 75%, respectively) ( Figure 7B ). However, anti-CD44 administration from week 1 to week 5 after transplant significantly impaired T-ALL engraftment and resulted in a striking reduction of leukemic burden in PB and spleen, which correlated with a marked decrease of splenomegaly compared with that in controls ( Figure  7 , B and C), indicating that anti-CD44 treatment impairs human T-ALL progression.
In a second group of mice, Ab treatment started when the disease was clearly established (at 5 weeks after transplant) and tumor burden reached up to 85% (55% ± 23%) of BM cells. In control IgG1-treated mice, T-ALL cells infiltrating the BM increased dramatically (up to 95%) during the next 2 weeks, and the incipient infiltration of PB observed at the onset of treatment resulted in a massive expansion (up to 70%). Despite the severity of the disease in those animals, anti-CD44 administration resulted in a significant drop of leukemia burden in the BM during the treatment period from weeks 5 to 9 after transplant, which paralleled an impaired T-ALL expansion in the PB, and this latter effect lasted for several weeks after the end of treatment ( Figure 7D) . As a consequence, the median survival of anti-CD44-treated mice was significantly prolonged (from 81 to 112 days) when compared with that of IgG1-treated controls ( Figure 7E ). Moreover, limiting dilution transplantation assays performed with T-ALL cells recovered from the BM of anti-CD44-treated or IgG1-treated mice provided formal proof that prolonged survival of the former correlated with a reduced frequency of leukemic cells with LIC activity. This correlation was observed even in poor responder mice, wherein anti-CD44 treatment was partially effective in terms of inhibition of leukemia progression. Indeed, LIC activity of CD44-targeted cells from a representative low responder (framed in Figure 7D ) was 40-fold reduced compared with LIC frequency of T-ALL cells from an IgG1-treated control (from 1:569 to 1:14, respectively). Accordingly, survival of secondary recipients receiving CD44-targeted T-ALL cells was markedly prolonged (from 65 to more than 225 days) compared with that of recipients receiving T-ALL cells from IgG1-treated mice (Figure Here, we report an in vivo model of human T-ALL, which recapitulates the behavior of deregulated T cell progenitors in T-ALL patients and the generation de novo of a clonal human T-ALL. The model relies on oncogenic signaling provided by constitutive NOTCH1 activation and uncovers the earliest stages of the leukemogenic process that determines the engraftment of preleukemic T cells in the BM and the subsequent establishment and progression of the disease (1, 11). The clinical relevance of this model is strengthened by the demonstration that the CD44 adhesion molecule is a direct NOTCH1 transcriptional target that mediates crucial cell interactions with the BM microenvironment that result in preleukemic engraftment and further support T-ALL LIC activity and disease progression. Our study thus provides information that opens avenues for delineating specific targeting therapies for fighting T-ALL relapse. Regardless of the particular oncogene driving T-ALL, NOTCH1 activation is known to be an early hallmark of T cell leukemogenesis and a key regulator of T-ALL LIC activity (13, 14) . Accordingly, there is a high selective pressure for NOTCH1 activation in T-ALL (35) . These findings concur with the fact that activatpresence of anti-CD44; however, we found no evidence of a direct impact of the CD44-HA interaction on cell survival or proliferation of T-ALL cells, at least when they were cultured on HA-coated plates (Supplemental Figure 5G and data not shown). Despite the CD44 ligand involved, formal proof that CD44-mediated function is critical for human T-ALL propagation in vivo was directly provided in experiments showing that leukemia engraftment was significantly impaired in NSG mice transplanted with T-ALL cells in which CD44 expression was silenced by enforced expression of a CD44-specific shRNA, as compared with cells transduced with a control scramble shRNA ( Figure 8F ). Collectively, these results provide evidence that CD44 expression is crucial for human T-ALL maintenance and progression in vivo, suggesting that CD44 targeting is a promising approach for treating T-ALL relapse.
Discussion
The multistep oncogenic process that underlies human T-ALL pathogenesis is still poorly understood, mainly because retrospective studies are not feasible in patients and no models reproducing the earliest stages of the human disease are yet available. + T-ALL1 cells of 5 NSG mice/ group at 11 weeks after transplant. *P < 0.05; **P < 0.01; ****P < 0.0001. jci.org Volume 128
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While the particular supportive signals provided in vivo by CD44 to T-ALL cells remain to be clarified, CD44 binding to its BM ligands may play a critical role. Particularly, HA influences most activities of CD44 (28, 44) and is required for normal BM hematopoiesis (45) , seeming a good candidate to provide niche supportive signals to preleukemic and leukemic T-ALL cells. However, we found no evidence of a direct effect of HA on survival or proliferation of primary T-ALL cells, at least in vitro, suggesting that other CD44 ligands, such as collagen, laminin, fibronectin, or osteopontin, may fulfill cell-survival functions in vivo (44) . Also, CD44 could function through functional regulation of additional molecules known to mediate HSPC interactions with the BM niche and cell survival, such as the CXCR4 chemokine receptor (30) (31) (32) . Supporting this view, previous findings have shown that CXCR4 function can be regulated via CD44 binding to HA (46, 47) , which concurs with our observation that ICN1 + CD44 hi DP cells have increased CXCR4-mediated function in vitro compared with normal DP thymocytes and can be mobilized in vivo in response to CXCR4 antagonists. Therefore, although NOTCH1 activation had no effect on surface expression levels of CXCR4 in our model, NOTCH1 signaling may contribute to T-ALL engraftment through the CXCR4/SDF1 signaling axis via CD44 induction. This possibility is further supported by the observation that CXCR4 is essential to the LIC activity of T-ALL cells, which were shown to be in direct contact with a vascular BM niche that expresses HA and produces SDF-1 (48, 49) . Since HA is the major component of the BM extracellular matrix (28, 44) , it is possible that the CD44-HA axis could ultimately control the highly dynamic interactions and promiscuous distribution of leukemia cells that migrate across the BM during T-ALL progression (50) .
T-ALL cells with LIC activity are thought to be responsible for relapse following chemotherapy (51) . Therefore, disruption of the specialized LIC niche is currently envisioned as a promising therapeutic strategy (11) . We now propose that CD44 targeting may represent a valuable therapy against T-ALL relapse, as anti-CD44 administration markedly impairs LIC activity of an established T-ALL xenograft and results in prolonged survival. Given that the observed therapeutic effect correlated with persistence of the anti-CD44 mAb on the surface of T-ALL cells, we suggest that impaired T-ALL LIC activity results from a compromised interaction of CD44 with the LIC-supportive niche. However, CD44 expression levels do not directly correlate with LIC activity, as primary T-ALL1 and T-ALL2 cells with distinct CD44 expression displayed similar LIC frequencies (1:113 and 1:143, respectively), suggesting that, as previously reported, other factors, such as glycosylation, may regulate the binding activity of CD44 (reviewed in ref. 25) .
Previous studies have highlighted the clinical significance of CD44 as a tumor-initiating marker in breast, colon, pancreatic, and liver cancers (25) and have demonstrated its contribution to the initiation of chronic and acute myeloid leukemias (52, 53) . Our study now extends the pathological role of CD44 to initiation and progression of T-ALL. Accordingly, CD44 is among the top 5% of genes overexpressed in human T-ALL with active NOTCH1 (54) , and its expression is a negative T-ALL prognostic factor associated with chemotherapy resistance (55) . Therefore, the observed therapeutic benefit of anti-CD44 treatment, together with the proposal that novel therapeutic interventions aimed ing NOTCH1 mutations are present in more than 60% of human T-ALL cases (3, 7) and that many NOTCH1 targets are crucial regulators of T-ALL pathogenesis (19-22, 36, 37) . Therefore, our model provides a valuable tool to decipher critical leukemogenic events that might be common to many subgroups of human T-ALL. Particularly, we show that CD44 upregulation may be one of the initial events that contribute to leukemogenesis in T-ALL patients. A link between Notch signaling and CD44 expression has been previously observed, though not formally established, in different cell types, including T cells (18, 38, 39) . We now show that CD44 is a direct NOTCH1 target, whose transcription is regulated in T-ALL cells by MAML1/CSL-binding to its proximal promoter, but also through dynamic interactions with a superenhancer, which is common to other NOTCH1 targets involved in development and cancer, such as IL7R (23) . Consequently, the important role that CD44 plays as a physiological mediator of HSPC anchoring within the BM niche during hematopoiesis can be extended to BM engraftment of aberrant T cell precursors (25) (26) (27) . Considering that normal T cell progenitors downregulate CD44 as part of their maturation program (16), natural NOTCH1 mutations or improved NOTCH1 activation in patients may be a crucial event to induce CD44-mediated exposure of preleukemic cells to critical supportive signals within the BM niche, which will further promote their expansion and eventually their transformation. Supporting the contribution of long-lasting interactions between preleukemic cells and their surrounding BM niche to disease development, ectopic generation of aberrant nontumorigenic DP T cells showing upregulated levels of CD44 typically precedes malignant transformation induced by Notch1 mutations in mice (17, 18, (38) (39) (40) . These results concur with our finding that NSG mice, which maintain long-term engraftment of human cells better than other mouse strains (24) , supported the generation de novo of an aggressive human T-ALL with latency longer than 6 months, while Rag2 -/-× γc -/-mice only supported short-term engraftment of aberrant ICN1 + DP T cells. Collectively, these data support our view that CD44 overexpression is an early hallmark of NOTCH1-associated T-ALL pathogenesis. However, the implication of CD44 in T-ALL pathogenesis has not been formally established. Using blocking anti-CD44 mAbs, we now provide evidence that CD44 critically controls the engraftment and expansion of human preleukemic T cells within the BM niche and the propagation of human T-ALL. The marked impact observed in vivo after treatment with the HP2/9 anti-CD44 mAb seems independent of cell loss due to CDC, as most mouse IgG1 mAbs are poor mediators of mouse complement activation (41) and CDC is not mediated in vitro by HP2/9. Moreover, HP2/9 administration also reduced leukemia burden in NSG mice, which lack CDC activity (34) . We can also discard a direct cytotoxic effect of the HP2/9 mAb bound on the cell surface, at least in vitro. However, we cannot formally rule out the possibility that myeloid cells present in immunodeficient mice eliminate T-ALL cells through Ab-dependent cellular cytotoxicity or phagocytosis (42, 43) , although it seems very unlikely considering that genetic silencing of CD44 was sufficient to impair T-ALL engraftment and progression in NSG mice. Therefore, our results suggest that blockage of CD44 by anti-CD44 mAbs may prevent T-ALL engraftment and progression by disrupting critical CD44-CD44 ligand-supportive interactions within the BM niche. jci. Cell cultures. Mycoplasma-free SupT1, HPB-ALL, and CUTLL1 T-ALL cell lines (57, 60) were cultured in RPMI 1640 medium (Lonza) supplemented with 10% FCS. For NOTCH1-signaling inhibition, cells were cultured with 200 nM CompE (Enzo Biochem Inc.), and DMSO vehicle was used as control.
T-ALL generation, xenotransplantion, and LIC activity assays. For human T-ALL generation, 3-to 5-day-old RAG-2 -/-× γc -/-(61) or 6-to 10-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; The Jackson Laboratory) mice were sublethally irradiated with 3.5 Gy or 1.5 Gy and subjected to intrahepatic (i.h.) or i.v. injection, respectively, with transduced human HSPCs or ETPs (1.0-1.5 × 10 6 cells/mice). LIC activity of human T-ALL cells arising de novo in the BM of NSG mice was assessed following their transplantation under limiting dilution conditions (from 10 2 to 10 6 cells/mouse) into secondary hosts. LIC frequency was calculated using ELDA software (http://bioinf.wehi.edu. au/software/elda/). For xenotransplantation assays, primary human T-ALL cells were transplanted by i.v. injection into 6-to 10-week-old RAG-2 -/-× γc -/-or NSG mice. LIC activity of patient T-ALLs was calculated with the ELDA software upon limiting dilution transplantation (3 to 10 5 cells/mouse) into secondary hosts.
Anti-CD44 mAb pretreatment and in vivo administration. For anti-CD44 pretreatment, ICN1-transduced ETPs or primary T-ALL cells were incubated at 4°C for 1 hour with 20 μg/ml of either blocking anti-CD44 mAb 515 (IgG1; BD Biosciences) or control mouse IgG1 prior to transplantation. When indicated, T-ALL cells were also pretreated with 100 μg/ml of anti-CD44 HP2/9 mAb (IgG1; 28, 29) . For in vivo administration, xenotransplanted mice were serially i.p. injected (3 times/week) with 200 μl of PBS containing either blocking anti-CD44 mAb HP2/9 or IgG1 starting at different times after transplant. In vivo persistence of HP2/9 mAb on the surface of T-ALL cells was analyzed by FACS using a PE-labeled goat anti-mouse IgG1 Ab (Southern Biotech). Total BM cellularity was calculated considering that 2 femurs represented 10% of total BM.
TCR-Vβ repertoire analysis and real-time quantitative PCR. Realtime quantitative PCR (qPCR) was performed as described (19) using TaqMan Gene Expression Assays (Applied Biosystems). To analyze T cell Vβ usage, cDNA from human DP cells was amplified by PCR using 22 different 5′ Vβ-specific primers and a common 3′ Cβ-specific primer, as previously described (62) .
Luciferase reporter assays. Human CD44 gene (ENSG00000026508) sequences of interest were amplified by conventional PCR and cloned into the pGL3-Promoter Luciferase Reporter Vector (Promega). Sitedirected mutagenesis of potential CSL-binding sites (HTGGGAM to HGTACCM for sites 1, 2, 3, and 5; and TTCCCAC to TGTACCC for site 4; bold letters indicate mutations that were made) was performed using specific primers and PCR. Luciferase reporter assays were performed as described (19) using SupT1 cells cotransfected with the CD44 luciferase reporter vectors and either MigR1-GFP, MigR1-ICN1, or MigR1-ICN1 and MigR1-dnMAML1 plus the constitutively active Renilla reniformis luciferase-producing vector pRL-CMV (Promega).
ChIP assays. To search for putative CSL/RBPJ-binding sites in human CD44, gene sequences (NCBI's Gene database; ENSG00000026508) covering 5 kb upstream of the TSS were anaat avoiding chemo-resistance and disease relapse may not need to target specific BM stroma components, but rather the ability of T-ALL cells to interact stochastically with promiscuous BM microenvironment components (50) , holds great promise for strategies that disrupt transient interactions of T-ALL cells with the supportive BM niche via CD44.
Methods
Human cell sample isolation and flow cytometry. Thymus samples were removed during corrective cardiac surgery of patients aged 1 month to 4 years. ETPs were isolated as described (19) from thymocyte suspensions obtained by centrifugation on Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS) using the Dynal CD34 Progenitor Cell Selection System (Life Technologies). HSPCs were obtained from FicollHypaque-purified CB samples by AutoMACS immunomagnetic sorting using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). Sorted populations were proved 99% or more CD34 + and negative for CD3, CD4, CD8, CD13, CD14, CD19, and CD56 lineage markers on reanalysis (Lin -
